Cerity Partners LLC Buys 4,005 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Cerity Partners LLC grew its stake in United Therapeutics Co. (NASDAQ:UTHR) by 82.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,886 shares of the biotechnology company’s stock after buying an additional 4,005 shares during the quarter. Cerity Partners LLC’s holdings in United Therapeutics were worth $3,184,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. B. Riley Wealth Advisors Inc. purchased a new position in United Therapeutics during the first quarter valued at approximately $219,000. Cetera Advisors LLC bought a new position in United Therapeutics in the 1st quarter worth $475,000. GAMMA Investing LLC boosted its holdings in United Therapeutics by 84.8% in the 2nd quarter. GAMMA Investing LLC now owns 390 shares of the biotechnology company’s stock worth $124,000 after buying an additional 179 shares during the period. DNB Asset Management AS increased its stake in United Therapeutics by 18.3% in the 2nd quarter. DNB Asset Management AS now owns 7,800 shares of the biotechnology company’s stock worth $2,485,000 after buying an additional 1,208 shares in the last quarter. Finally, Bank & Trust Co bought a new stake in United Therapeutics during the second quarter valued at about $420,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics

In other news, Director Nilda Mesa sold 224 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $412.28, for a total value of $92,350.72. Following the transaction, the director now directly owns 5,783 shares in the company, valued at approximately $2,384,215.24. This represents a 3.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Christopher Causey sold 510 shares of United Therapeutics stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total transaction of $192,081.30. Following the sale, the director now owns 3,675 shares of the company’s stock, valued at $1,384,115.25. The trade was a 12.19 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 127,227 shares of company stock worth $47,398,820. 11.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on UTHR. Wells Fargo & Company increased their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. The Goldman Sachs Group increased their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group boosted their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Stock Down 2.0 %

NASDAQ UTHR opened at $370.49 on Friday. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The firm has a market capitalization of $16.54 billion, a price-to-earnings ratio of 16.27, a PEG ratio of 1.10 and a beta of 0.56. The company has a fifty day moving average of $367.77 and a two-hundred day moving average of $335.19.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.38 EPS. Equities research analysts anticipate that United Therapeutics Co. will post 25.22 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.